hemotune AG was selected for Phase I funding by the EU Horizon 2020 Small and Medium Enterprises (SME) Instrument. The SME Instrument is part of the research and innovation program by the EU and supports groundbreaking innovative ideas for products, services or processes that are ready to conquer global markets. With only about 8% of applications being funded, the selection of hemotune is also a great honor highlighting hemotune's disruptive potential in the blood purification field. The SME Phase I funding will be used to further de-risk hemotune's magnetic blood purification technology in terms of technical and market feasibility.

Over the last months we have welcomed several new team members adding complementary expertise to the team. Dr. Edouard Fonck is focussing on Business Development while Dr. Ursina Haltinner is responsible for Regulatory and Quality Affairs and Max Bär is working on the Nanosorbent development.